Every 10-Q that Progyny, Inc. (PGNY) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow PGNY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PGNY filings page.
Progyny, a fertility and women’s health benefits company, reported second‑quarter 2026 revenue of $350,511 (in thousands), up from $332,874 (in thousands) a year earlier, with fertility benefits and integrated pharmacy services both contributing. Gross margin improved to 25.5% from 23.7%.
Operating expenses declined as a share of revenue to 14.1%, while stock‑based compensation fell to $20,478 (in thousands) from $32,383 (in thousands). Income from operations rose to $40,003 (in thousands), and net income increased to $28,052 (in thousands), or $0.34 diluted EPS. Adjusted EBITDA was $62,104 (in thousands), a 17.7% margin. As of June 30, 2026, Progyny reported $715,836 (in thousands) of total assets and stockholders’ equity of $453,257 (in thousands), and it actively returned capital, repurchasing 6,700,337 shares in the first half of 2026 at an average price of $22.08 per share.
Progyny, Inc. reported higher profitability for the quarter ended March 31, 2026, as modest revenue growth combined with lower costs and stock-based compensation. Revenue rose to $328.5 million from $324.0 million, while net income increased to $24.2 million from $15.1 million.
Gross margin improved to 25.3%, reflecting efficiencies in care management and lower stock-based compensation. Adjusted EBITDA was $56.6 million, or 17.2% of revenue. The company ended the quarter with $225.1 million in cash and marketable securities and no borrowings on a $200 million credit facility.
Progyny served 595 clients and about 7.2 million covered lives, with ART cycles of 15,647 and stable utilization. It completed a $200 million share repurchase program, buying back 5.5 million shares in the quarter, which reduced shares outstanding and supported EPS growth to $0.29 diluted.
Progyny, Inc. (PGNY) reported stronger Q3 2025 results. Revenue rose to $313.3M from $286.6M, with gross profit of $72.8M. Operating income increased to $21.5M and net income reached $13.9M, or $0.15 diluted EPS. For the first nine months, revenue was $970.3M and net income was $46.0M, reflecting solid year-to-date performance.
Liquidity remained healthy: cash and cash equivalents were $134.0M and marketable securities were $211.2M at quarter end. Operating cash flow for the nine months was $156.0M. The company entered a $200M revolving credit facility maturing in 2030, with no borrowings outstanding, and later authorized a new $200M share repurchase program in November 2025. Total assets were $795.2M and stockholders’ equity was $560.0M. As of October 31, 2025, 86,211,654 common shares were outstanding.
Client base and utilization supported growth: Q3 fertility benefits revenue was $201.9M and pharmacy benefits revenue was $111.4M. The company closed the Benefit Bump acquisition for $10.5M to extend family support offerings.
Progyny (PGNY) filed its Q2-25 10-Q showing solid top-line momentum and margin expansion, tempered by higher opex and tax expense.
- Revenue rose 9.5% YoY to $332.9 m; pharmacy contributed 36% while core fertility benefits grew 10.5%. 1H-25 revenue is up 12.9% to $656.9 m.
- Gross profit improved 15.7% to $79.0 m; gross margin expanded 130 bp to 23.7% as case-rate pricing and pharmacy rebates offset service-cost inflation.
- Operating income increased 17.7% to $24.4 m; however, a higher effective tax rate (36.8% vs 34.2%) limited net income growth to 3.8% ($17.1 m, $0.19 diluted EPS).
- For 1H-25, net income slipped 3.6% to $32.2 m, but diluted EPS rose to $0.36 on a 10% lower share count following 2024 buybacks.
- Cash & M-secs stand at $305.1 m, up $18.1 m YoY; operating cash flow strengthened 28% to $105.3 m. No debt; a new $200 m undrawn revolver was signed 1 Jul 25.
- Balance sheet: current ratio 2.7x; equity climbed 22% to $515.0 m. Accounts receivable (+16%) and payables (+48%) rose with volume.
- Operations: ART cycles grew 8.8% to 16,938 while overall member utilization held at 0.55%. Client count reached 542 covering 6.8 m lives.
- M&A: closed $10.5 m Benefit Bump acquisition in Jan-25; integration ongoing.
Overall, PGNY continues to outpace the fertility-benefits market, generating healthy cash and maintaining a debt-free profile, though investors should watch rising opex, receivables exposure and tax headwinds.